As of today (2022-05-20), VistaGen Therapeutics's share price is $1.11. VistaGen Therapeutics's Tangible Book per Share of Dec. 2021 for the quarter that ended in Dec. 2021 was $0.39. Hence, VistaGen Therapeutics's Price to Tangible Book Ratio of today is 2.87.
The historical rank and industry rank for VistaGen Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
VTGN'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.44 Med: 7.71 Max: 28.41
Current: 2.85
During the past 13 years, VistaGen Therapeutics's highest Price to Tangible Book Ratio was 28.41. The lowest was 2.44. And the median was 7.71.
VTGN's Price-to-Tangible-Book is ranked worse than 56.77% of 1344
companies
in the Biotechnology industry
Industry Median: 2.46
vs VTGN: 2.85
A closely related ratio is called PB Ratio. As of today, VistaGen Therapeutics's share price is $1.11. VistaGen Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2021 was $0.39. Hence, VistaGen Therapeutics's P/B Ratio of today is 2.87.
VistaGen Therapeutics Price-to-Tangible-Book Historical Data
The historical data trend for VistaGen Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar12
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Price-to-Tangible-Book
28.41
3.09
7.71
-
4.18
VistaGen Therapeutics Quarterly Data
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Price-to-Tangible-Book
2.87
4.18
7.05
6.67
5.04
Competitive Comparison
For the Biotechnology subindustry, VistaGen Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VistaGen Therapeutics Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
VistaGen Therapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.03(2.63%) Volume: 698,124 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
